Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | LYN | P07948 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 5/20 | 0.49 |
| ▸ | ABL1 | P00519 | 9/20 | 0.47 |
| ▸ | BCR | P11274 | 7/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 1/20 | 0.46 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12398490 | 0.97 | CSF1R (0.48) | CSF1RLYNKITBRAFABL1 | |
| SCHEMBL12398489 | 0.93 | BRAF (0.51) | CSF1RLYNKITBRAFABL1 | |
| SCHEMBL12397954 | 0.93 | BRAF (0.57) | CSF1RLYNKITBRAFABL1 | |
| SCHEMBL12398059 | 0.90 | BRAF (0.55) | CSF1RLYNKITBRAFABL1 | |
| SCHEMBL15869647 | 0.88 | BRAF (0.47) | CSF1RLYNKITBRAFABL1 | |
| SCHEMBL12397301 | 0.88 | DDR2 (0.54) | KITABL1BCRDDR1DDR2 | |
| SCHEMBL12397996 | 0.88 | BRAF (0.56) | BRAFABL1BCRGPR142 | |
| SCHEMBL12398154 | 0.87 | GPR142 (0.53) | CSF1RLYNKITBRAFABL1 | |
| SCHEMBL12397967 | 0.87 | BRAF (0.56) | BRAFABL1BCRGPR142 | |
| SCHEMBL12398477 | 0.86 | ABL1 (0.61) | CSF1RLYNKITBRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889665-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889665-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| WO-2009003999-A2 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | MKI67, CCNA1, CCNT1 | CSF1R 594/4885LYN 2048/4885KIT 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.